The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Corgard     (2R,3S)-5-[2-hydroxy-3- (tert...

Synonyms: Nadololum, nadolol, Anabet, Corgaretic, Solgol, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of nadolol


Psychiatry related information on nadolol


High impact information on nadolol

  • The initial dose of nadolol was 80 mg orally once daily, with adjustment according to the resting heart rate; isosorbide mononitrate was given in increasing doses, beginning at 20 mg once a day at bed time and rising over the course of one week to 40 mg orally twice a day, unless side effects occurred [11].
  • Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding [11].
  • Redistribution of cardiac output to the kidneys during oral nadolol administration [12].
  • In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline produced consistent negative inotropic effects [13].
  • CONCLUSIONS: Our trial showed that ligation was more effective than nadolol plus isosorbide-5-mononitrate in the prevention of variceal rebleeding, with similar complications in both treatment modalities [14].

Chemical compound and disease context of nadolol


Biological context of nadolol


Anatomical context of nadolol

  • METHODS AND RESULTS: A double-blind, randomized, placebo-controlled, crossover trial of nadolol versus placebo was performed in 20 patients with stable coronary artery disease [20].
  • (ii) Chronic treatment with nadolol or carvedilol significantly increased beta-AR densities in lung membranes by 719% and 828%, respectively [24].
  • The effects of alpha-AS (50 microM phenylephrine and 1 microM nadolol) and beta-AS (0.05 microM isoproterenol) on contraction and either cytosolic Ca2+ (Cai) or pH(i) were assessed in adult rat ventricular myocytes bathed in bicarbonate buffer (pH 7.36 +/- 0.05) [25].
  • A total of 49 cirrhotic patients with varices at risk of bleeding, without prior variceal bleeding, were investigated by hepatic vein catheterization before and after 1 to 3 months of chronic treatment with nadolol or nadolol plus isosorbide mononitrate, and were followed during treatment for up to 5 years [26].
  • Nadolol induced no significant changes in the thyroid hormones measured [27].

Associations of nadolol with other chemical compounds


Gene context of nadolol


Analytical, diagnostic and therapeutic context of nadolol

  • In a double-blind, placebo-controlled, crossover design, patients received 80 to 320 mg of nadolol for six weeks while continuing their previous therapeutic regimen [36].
  • The percentages of patients who had not bled 1 and 2 years after the inclusion were 100 and 94.4% for the nadolol group and 81.2 and 70.2% for the control group (p less than 0.02), respectively [28].
  • We conclude that beta-blockers can be compared by ECG recordings and that nadolol is different from the other beta-blockers without intrinsic sympathomimetic activity [37].
  • Nadolol, 120 and 240 mg daily, reduced essential tremor in a placebo-controlled double-blind study [38].
  • CONCLUSIONS: Chronic therapy with nadolol decreased portal blood flow velocity and volume, and increased splanchnic and renal impedance indices [39].


  1. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. Poynard, T., Calès, P., Pasta, L., Ideo, G., Pascal, J.P., Pagliaro, L., Lebrec, D. N. Engl. J. Med. (1991) [Pubmed]
  2. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. Villanueva, C., Balanzó, J., Novella, M.T., Soriano, G., Sáinz, S., Torras, X., Cussó, X., Guarner, C., Vilardell, F. N. Engl. J. Med. (1996) [Pubmed]
  3. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Merkel, C., Marin, R., Enzo, E., Donada, C., Cavallarin, G., Torboli, P., Amodio, P., Sebastianelli, G., Sacerdoti, D., Felder, M., Mazzaro, C., Beltrame, P., Gatta, A. Lancet (1996) [Pubmed]
  4. Beta blockade with nadolol in patient with congestive heart-failure. Vukovich, R., Sasahara, A., Sanchez-Zambrano, S., Belko, J. Lancet (1978) [Pubmed]
  5. Nadolol and papilledema. Kaul, S., Wong, M., Singh, B.N., Hepler, R.S. Ann. Intern. Med. (1982) [Pubmed]
  6. Nadolol as a treatment for akathisia. Ratey, J.J., Sorgi, P., Polakoff, S. The American journal of psychiatry. (1985) [Pubmed]
  7. Effects of nadolol on blood pressure, sleep efficiency, and sleep stages. Kales, A., Bixler, E.O., Vela-Bueno, A., Cadieux, R.J., Manfredi, R.L., Bitzer, S., Kantner, T. Clin. Pharmacol. Ther. (1988) [Pubmed]
  8. Use of a long acting peripheral beta blocker, nadolol, in panic disorder. Tollefson, G. Journal of clinical psychopharmacology. (1984) [Pubmed]
  9. Central beta-adrenergic modulation of cognitive flexibility. Beversdorf, D.Q., White, D.M., Chever, D.C., Hughes, J.D., Bornstein, R.A. Neuroreport (2002) [Pubmed]
  10. Titration of nadolol in the treatment of hypertension. Papadoyannis, D.E., Papazachos, G.A., Karatzas, N.B. Eur. J. Clin. Pharmacol. (1982) [Pubmed]
  11. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. Villanueva, C., Miñana, J., Ortiz, J., Gallego, A., Soriano, G., Torras, X., Sáinz, S., Boadas, J., Cussó, X., Guarner, C., Balanzó, J. N. Engl. J. Med. (2001) [Pubmed]
  12. Redistribution of cardiac output to the kidneys during oral nadolol administration. Textor, S.C., Fouad, F.M., Bravo, E.L., Tarazi, R.C., Vidt, D.G., Gifford, R.W. N. Engl. J. Med. (1982) [Pubmed]
  13. Functional beta3-adrenoceptor in the human heart. Gauthier, C., Tavernier, G., Charpentier, F., Langin, D., Le Marec, H. J. Clin. Invest. (1996) [Pubmed]
  14. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Lo, G.H., Chen, W.C., Chen, M.H., Hsu, P.I., Lin, C.K., Tsai, W.L., Lai, K.H. Gastroenterology (2002) [Pubmed]
  15. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. Merkel, C., Gatta, A., Donada, C., Enzo, E., Marin, R., Amodio, P., Torboli, P., Angeli, P., Cavallarin, G., Sebastianelli, G. Hepatology (1995) [Pubmed]
  16. Minoxidil, nadolol, and a diuretic. Once-a-day therapy for resistant hypertension. Spitalewitz, S., Porush, J.G., Reiser, I.W. Arch. Intern. Med. (1986) [Pubmed]
  17. Clinical features and prognosis of patients with out of hospital cardiac arrest and a normal electrophysiologic study. Morady, F., DiCarlo, L., Winston, S., Davis, J.C., Scheinman, M.M. J. Am. Coll. Cardiol. (1984) [Pubmed]
  18. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. Leenen, F.H., Davies, R.A., Fourney, A. Clin. Pharmacol. Ther. (1998) [Pubmed]
  19. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Nakashima, H., Gerlach, U., Schmidt, D., Nattel, S. Cardiovasc. Res. (2004) [Pubmed]
  20. Morning increase in ambulatory ischemia in patients with stable coronary artery disease. Importance of physical activity and increased cardiac demand. Parker, J.D., Testa, M.A., Jimenez, A.H., Tofler, G.H., Muller, J.E., Parker, J.O., Stone, P.H. Circulation (1994) [Pubmed]
  21. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Merkel, C., Sacerdoti, D., Bolognesi, M., Enzo, E., Marin, R., Bombonato, G., Angeli, P., Gatta, A. Hepatology (1997) [Pubmed]
  22. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. White, W.B. Arch. Intern. Med. (1986) [Pubmed]
  23. Enhancement of nadolol elimination by activated charcoal and antibiotics. du Souich, P., Caillé, G., Larochelle, P. Clin. Pharmacol. Ther. (1983) [Pubmed]
  24. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Callaerts-Vegh, Z., Evans, K.L., Dudekula, N., Cuba, D., Knoll, B.J., Callaerts, P.F., Giles, H., Shardonofsky, F.R., Bond, R.A. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  25. Different effects of alpha- and beta-adrenergic stimulation on cytosolic pH and myofilament responsiveness to Ca2+ in cardiac myocytes. Gambassi, G., Spurgeon, H.A., Lakatta, E.G., Blank, P.S., Capogrossi, M.C. Circ. Res. (1992) [Pubmed]
  26. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Merkel, C., Bolognesi, M., Sacerdoti, D., Bombonato, G., Bellini, B., Bighin, R., Gatta, A. Hepatology (2000) [Pubmed]
  27. Nadolol, propranolol, and thyroid hormones: evidence for a membrane-stabilizing action of propranolol. Reeves, R.A., From, G.L., Paul, W., Leenen, F.H. Clin. Pharmacol. Ther. (1985) [Pubmed]
  28. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Idéo, G., Bellati, G., Fesce, E., Grimoldi, D. Hepatology (1988) [Pubmed]
  29. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Lo, G.H., Lai, K.H., Cheng, J.S., Chen, M.H., Huang, H.C., Hsu, P.I., Lin, C.K. Hepatology (2000) [Pubmed]
  30. Increased infarct size in uremic rats: reduced ischemia tolerance? Dikow, R., Kihm, L.P., Zeier, M., Kapitza, J., Törnig, J., Amann, K., Tiefenbacher, C., Ritz, E. J. Am. Soc. Nephrol. (2004) [Pubmed]
  31. beta3-adrenoceptor control the cystic fibrosis transmembrane conductance regulator through a cAMP/protein kinase A-independent pathway. Leblais, V., Demolombe, S., Vallette, G., Langin, D., Baró, I., Escande, D., Gauthier, C. J. Biol. Chem. (1999) [Pubmed]
  32. In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use. Schiffelers, S.L., Blaak, E.E., Saris, W.H., van Baak, M.A. Clin. Pharmacol. Ther. (2000) [Pubmed]
  33. Oxytocin-induced renin secretion in conscious rats. Huang, W., Sjöquist, M., Skott, O., Stricker, E.M., Sved, A.F. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) [Pubmed]
  34. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. Sanders, V.M., Baker, R.A., Ramer-Quinn, D.S., Kasprowicz, D.J., Fuchs, B.A., Street, N.E. J. Immunol. (1997) [Pubmed]
  35. Catecholaminergic control of NK cell cytolytic activity regulatory factors in the spleen. Dokur, M., Boyadjieva, N., Sarkar, D.K. J. Neuroimmunol. (2004) [Pubmed]
  36. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Foster, N.L., Newman, R.P., LeWitt, P.A., Gillespie, M.M., Larsen, T.A., Chase, T.N. Ann. Neurol. (1984) [Pubmed]
  37. Comparison of four beta-blockers as assessed by 24-hour ECG recording. Escoubet, B., Leclercq, J.F., Maison-Blanche, P., Poirier, J.M., Gourmel, B., Delhotal-Landes, B., Coumel, P. Clin. Pharmacol. Ther. (1986) [Pubmed]
  38. Nadolol in essential tremor. Koller, W.C. Neurology (1983) [Pubmed]
  39. Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. Bolognesi, M., Sacerdoti, D., Merkel, C., Bombonato, G., Enzo, E., Gatta, A. J. Hepatol. (1997) [Pubmed]
WikiGenes - Universities